Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11

Emerging Infectious Diseases

Volumn 17, Issue 11, 2011, Pages 2043-2046

  Sleeman, Katrina ^a   Sheu, Tiffany G ^a,b   Moore, Zack ^c   Kilpatrick, Susan ^c   Garg, Shikha ^a   Fry, Alicia M ^a   Gubareva, Larisa V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASSAY; CONTROLLED STUDY; GENE MUTATION; HEMAGGLUTININ GENE; IC 50; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MOLECULAR PHYLOGENY; NEURAMINIDASE GENE; NEURAMINIDASE INHIBITION ASSAY; NONHUMAN; PYROSEQUENCING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; VIRUS GENE;

EID: 84930485207     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1711.110787     Document Type: Article

References (15)

1. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of Influenza viruses resistant to neur-aminidase inhibitors in global surveillance during the fi rst 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395-402. doi:10.1128/AAC.01339-05
2. Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA, et al. Oseltamivir-resistant Influenza A and B viruses pre- and post-viral therapy in children and young adults with cancer. Pediatr Infect Dis J. 2011;30:284-8. doi:10.1097/INF.0b013e3181ff863b
3. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of Influenza A and Influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 Influenza seasons. Clin Infect Dis. 2006;43:439-44. doi:10.1086/505868
4. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with Influenza B virus. J Infect Dis. 1998;178:1257-62. doi:10.1086/314440
5. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, et al. Emergence of Influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-42. doi:10.1001/ jama.297.13.1435
6. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, et al. Comparison of the clinical effectiveness of osel-tamivir and zanamivir against Influenza infection in children. Clin Infect Dis. 2008;47:339-45. doi:10.1086/589748
7. Hurt AC, Kimm-Breschkin JL, McDonald M, Barr IG, Komadina N, Hampson AW. Identifi cation of a human Influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Res. 2004;103:205-11. doi:10.1016/j.virusres.2004.02.035
8. Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, et al. Neuraminidase inhibitor-resistant and -sensitive Influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother. 2006;50:1872-4. doi:10.1128/AAC.50.5.1872-1874.2006
9. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human Influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-92. doi:10.1128/AAC.00555-08
10. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. Detection of antiviral resistance and genetic lineage markers in infl u-enza B virus neuraminidase using pyrosequencing. Antiviral Res. 2010;85:354-60. doi:10.1016/j.antiviral.2009.10.022
11. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic Influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis. 2010;51:983-4. doi:10.1086/656439
12. van der Vries E, Stelma FF, Boucher CAB. Emergence of a multi-drug-resistant pandemic Influenza A(H1N1) virus. N Engl J Med. 2010;363:1381-2. doi:10.1056/NEJMc1003749
13. Hurt AC, Holien JK, Barr IG. In vitro generation of neuramini-dase inhibitor resistance in A(H5N1) Influenza viruses. Antimicrob Agents Chemother. 2009;53:4433-40. doi:10.1128/AAC.00334-09
14. Baz M, Abed Y, McDonald J, Boivin G. Characterization of a multidrug-resistant Influenza A/H3N2 virus shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006;43:1555-61. doi:10.1086/508777
15. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, et al. Detection of E119V and E119I mutations in Influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother. 2010;54:1834-41. doi:10.1128/AAC.01608-09